Arcus sets $17.50 share price for $250 million equity financing

Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add capital to its own balance sheet rather than provide an exit for existing holders. Underwriters also received a 30-day option to purchase up to 2,142,857 additional shares.

The offering is expected to close on October 23, subject to customary conditions. It would strengthen funding capacity for the late-stage drug developer, whose portfolio targets cancer and immune diseases, while diluting existing investors' ownership. The headline amount is before underwriting discounts, commissions and expenses. The optional additional shares are separate from the base deal and should not be treated as already issued or as guaranteed extra proceeds.

Sources:

• investors.arcusbio.com
• Issuer release via StockTitan